Celvionics is building a focused therapeutic pipeline around precision immunology, antibody engineering, and biologic innovation. Programs remain static here until formal company updates are released.
A lead antibody therapeutic program focused on immune pathway modulation for severe autoimmune disease.
Disease Area: Autoimmune Disease | Target: Immune Pathway | Stage: Phase 2 | Status: Active
Development focus: clinical translation, biomarker strategy, and patient-centered therapeutic positioning.
A preclinical antibody program evaluating a rare neurological disorder with high unmet need.
Disease Area: Rare Neurological Disorder | Target: Antibody Target | Stage: Preclinical | Status: Research
CLV 303 | Inflammatory Disease | Target: Immune Modulation | Stage: Discovery | Status: Ongoing
Celvionics welcomes scientific collaboration, platform partnerships, and development discussions with organizations advancing targeted immunology and biologic therapeutics.
